Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 1/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | EPOR | P19235 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388781 | 1.00 | FOS (0.56) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL12500127 | 0.92 | LTB4R (0.54) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL3135246 | 0.90 | LTB4R (0.58) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL3135249 | 0.90 | LTB4R (0.58) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL7494930 | 0.85 | PAM (0.59) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL9044877 | 0.85 | PAM (0.59) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL27550325 | 0.85 | CHRM2 (0.51) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL16710517 | 0.81 | NPC1 (0.65) | BCHEGRIK1GRIK2RELA | |
| SCHEMBL27996278 | 0.81 | RELA (0.57) | FOSJUNBCHEGRIK1GRIK2 | |
| SCHEMBL28439042 | 0.81 | NPC1 (0.69) | FOSJUNBCHEMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-24 | — | — | US | disclosed |
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-24 | — | — | US | disclosed |
| EP-3720842-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | Ontario Institute For Cancer Research (CA) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| EP-1194421-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2005-10-12 | — | — | EP | disclosed |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | disclosed |
| EP-1194421-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1194421-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6225330-B1 | Selective NPY (Y5) antagonists (tricyclics) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | KAT7, AADAC, HDAC7 | FOS 3161/4885JUN 4106/4885BCHE 1794/4885 |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | FOS 1878/4885JUN 2176/4885BCHE 1145/4885 |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | AADAC, HDAC8, KAT8 | FOS 2836/4885JUN 4127/4885BCHE 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.